Heather Licke, MD
Family Medicine · Saint Francis, KSNPI 1093026429
Payments from drug & device makers
Across 104 payments — averaging $14.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$419
- Amgen$211
- Sunovion Pharmaceuticals Inc.$147
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$97
- Johnson & Johnson$77
- Novo Nordisk$74
- plus $491 from 15 others
What the payments were for
- Food & beverage$1,515100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 31 | $419 |
| Amgen | 15 | $211 |
| Sunovion Pharmaceuticals Inc. | 11 | $147 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 5 | $97 |
| Johnson & Johnson | 4 | $77 |
| Novo Nordisk | 5 | $74 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $63 |
| Sumitomo Pharma America, Inc. | 4 | $63 |
| Pfizer | 4 | $54 |
| Biohaven Pharmaceutical Holding Company Ltd. | 4 | $53 |
| Lilly USA, LLC | 3 | $46 |
| AstraZeneca | 3 | $39 |
| Myriad Women's Health, Inc. | 1 | $37 |
| Sanofi | 2 | $30 |
| Boehringer Ingelheim | 1 | $22 |
| Bioventus LLC | 1 | $19 |
| Astellas Pharma US Inc | 1 | $14 |
| Vertex | 1 | $14 |
| Novartis | 1 | $13 |
| Merck | 1 | $12 |
| Phathom Pharmaceuticals, Inc. | 1 | $11 |
How this compares
$1,515 in reported general payments places this provider in the 65th percentile of 1,469 family medicine providers in Kansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 508 | $308,815 |
| MounjaroTirzepatide | 122 | $129,230 |
| XareltoRivaroxaban | 170 | $97,027 |
| GemtesaVibegron | 197 | $92,546 |
| OzempicSemaglutide | 91 | $86,753 |
| VraylarCariprazine Hcl | 57 | $84,093 |
| RybelsusSemaglutide | 85 | $82,395 |
| MyrbetriqMirabegron | 174 | $82,063 |
| TrulicityDulaglutide | 69 | $72,928 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 94 | $60,692 |
| JardianceEmpagliflozin | 91 | $56,007 |
| JanuviaSitagliptin Phosphate | 90 | $55,973 |
| LinzessLinaclotide | 75 | $41,799 |
| FarxigaDapagliflozin Propanediol | 63 | $39,837 |
| ViberziEluxadoline | 22 | $34,553 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $54 | $308,815508 claims |
| Lilly USA, LLCMounjaro, Trulicity | $46 | $202,157191 claims |
| AbbVieVraylar, Linzess, Viberzi, Creon | $419 | $177,370174 claims |
| Novo NordiskOzempic, Rybelsus | $74 | $169,148176 claims |
| Boehringer IngelheimJardiance, Spiriva Respimat, Tradjenta, Trijardy Xr | $22 | $103,098183 claims |
| Johnson & JohnsonXarelto | $77 | $97,027170 claims |
| MerckJanuvia, Janumet Xr, Janumet, Belsomra | $12 | $93,046156 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $63 | $92,546197 claims |
| Astellas Pharma US IncMyrbetriq | $14 | $82,063174 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $39 | $68,89497 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $97 | $19,34512 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $63 | $11,46324 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 1,469 family medicine providers in Kansas.
Other family medicine in Saint Francis
- Terry PolingWichita$24.2M
- Richard GloverNewton$19.6M
- Daniel DickersonLenexa$13.6M
- Patrick YaoOlathe$11.7M
- Michael RauschAugusta$8.1M
- Terry KleinWichita$5.9M
- Richard EgelhofWichita$4.1M
- Thomas KleinWichita$3.4M
- Troy HoldemanNewton$3.2M
- Stacy SlechtaNewton$3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.